Abbott Laboratories $ABT Shares Sold by Norris Perne & French LLP MI

Norris Perne & French LLP MI reduced its stake in Abbott Laboratories (NYSE:ABT) by 2.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 209,493 shares of the healthcare product maker’s stock after selling 5,648 shares during the period. Abbott Laboratories accounts for about 1.7% of Norris Perne & French LLP MI’s investment portfolio, making the stock its 21st biggest holding. Norris Perne & French LLP MI’s holdings in Abbott Laboratories were worth $26,247,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ABT. Brighton Jones LLC raised its holdings in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares during the last quarter. United Bank raised its holdings in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after buying an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC raised its holdings in shares of Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after buying an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board raised its holdings in shares of Abbott Laboratories by 25.6% during the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after buying an additional 292,547 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $100.58 on Tuesday. Abbott Laboratories has a 12 month low of $99.05 and a 12 month high of $139.06. The stock has a market cap of $175.17 billion, a price-to-earnings ratio of 27.04, a PEG ratio of 1.60 and a beta of 0.79. The stock’s 50 day moving average price is $108.74 and its 200 day moving average price is $119.53. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the previous year, the company earned $1.34 earnings per share. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.5%. Abbott Laboratories’s payout ratio is presently 67.74%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Piper Sandler cut their price target on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a report on Friday, January 23rd. Argus cut their price target on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Leerink Partners cut their price target on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a report on Friday, January 30th. Oppenheimer cut their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $134.58.

Insider Activity

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares in the company, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock valued at $353,097 over the last 90 days. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.